National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.2) 2023

Overview

The National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.2) 2023, enacted in 2023 under the authority of the National Health Act 1953, addresses the need for targeted adjustments in the prices of pharmaceutical items to ensure cost-effectiveness and accessibility in the healthcare system. This determination was issued by Nikolai Tsyganov, the Assistant Secretary of the Pricing and PBS Policy Branch, Technology Assessment and Access Division within the Department of Health and Aged Care, acting on behalf of the Minister for Health and Aged Care. The policy objective of this instrument is to exercise ministerial discretion in reducing the approved ex-manufacturer prices of certain pharmaceutical items to better align with the overarching goals of the national health framework, which include enhancing the affordability and availability of essential medications. This legislative instrument allows for specific brands of pharmaceutical items to either have their prices reduced by a lower percentage than otherwise applicable, or to not undergo any price reduction at all. This approach ensures that the pricing adjustments are tailored to specific circumstances and needs, balancing the requirements of cost containment with the imperative to provide effective and accessible healthcare solutions. The implementation of this determination follows a structured approach, with specific commencement dates for the various provisions outlined within the instrument, ensuring a clear and orderly transition into effect.

Scope and Application

The National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No. 2) 2023, made under subsection 99ACF(3) of the National Health Act 1953, applies to the pricing of pharmaceutical items listed in its schedules. This determination impacts pharmaceutical brands and their approved ex-manufacturer prices, and it specifically targets brands of pharmaceutical items, including combination items, that are subject to price reductions as of a catch-up price reduction day. The determination applies across the Commonwealth of Australia, reflecting its national scope. It specifies particular brands and forms of pharmaceutical items that will either experience a lower percentage price reduction or no price reduction at all, as detailed in the schedules of the determination. This legislative instrument does not explicitly state exclusions or thresholds but operates within the broader framework of the National Health Act 1953, which may include other provisions governing its application. The effectiveness of this determination is contingent upon its registration, and its provisions may be further elaborated or amended through subordinate instruments.

Key Provisions

The National Health (April 2023 Price Reductions) (Exercise of Ministerial discretion) Determination (No.2) 2023, under the National Health Act 1953, establishes specific price adjustments for certain pharmaceutical items. The determination specifies reduced price percentages for certain brand pharmaceutical items, as listed in Schedules 1 and 3, and excludes certain brands from price reductions, as listed in Schedule 2 (sections 5, 6 and 7). These adjustments are effective from the day the instrument is registered, as outlined in section 2. The authority for this determination is granted under subsection 99ACF(3) of the Act. The obligations imposed by this Act include the mandatory adjustments of the approved ex-manufacturer prices and claimed prices, where applicable, for the pharmaceutical items specified in the schedules. Pharmaceutical companies must ensure that the prices of the listed brands are reduced or not reduced as specified, depending on the item's inclusion in Schedules 1, 2, or 3. Failure to comply with these price adjustments could result in non-compliance with the Act and may attract penalties or other consequences. There are no specific offences, penalties, or civil/criminal consequences outlined within the determination itself. However, non-compliance with the Act and its associated regulations may lead to enforcement actions by the relevant authorities. These actions could include fines, legal proceedings, or other remedies available under the National Health Act 1953 and other applicable legislation. The specific penalties would depend on the nature and severity of the non-compliance.